Recent Updates — BHST

BioHarvest Sciences announced that its proprietary Olive Cell composition has completed development and the self-affirmed GRAS process, reaching commercial readiness. The high-potency Verbascoside ingredient is now available for licensing and manufacturing through the company's CDMO business at its GMP facility. Preliminary in-vitro data showed dose-dependent reductions in lipid accumulation and collagen production in liver models. BioHarvest Sciences Inc. is a biotechnology company pioneering Botanical Synthesis technology to produce plant-derived compounds.

Tate & Lyle PLC and BioHarvest Sciences Inc. announced a significant milestone in their collaborative next-generation sweetener development program, confirming that BioHarvest’s Botanical Synthesis™ platform can produce the targeted solution. This progress validates the technology's potential to offer sustainable, consistent plant-derived ingredients for food and beverage manufacturers seeking sugar and calorie reduction. The announcement builds on an expanded collaboration initiated in May 2026 and underscores the viability of using botanical synthesis as a Contract Development and Manufacturing Organization (CDMO) service. BioHarvest Sciences Inc. operates as a botanical synthesis company leveraging proprietary technology to develop and manufacture plant-based compositions without growing underlying plants.

BioHarvest Sciences Inc. announced the registration of its common shares on the Tel Aviv Stock Exchange (TASE), achieving dual listing alongside its existing Nasdaq Capital Market listing. Trading on TASE commenced on September 8, 2026, under the symbol BHST. The company registered approximately 22.7 million outstanding shares for trading, along with up to 4.5 million additional shares available for future issuance under equity incentive plans and warrants. This expansion provides investors in Israel with direct access to the company's equity. BioHarvest Sciences Inc. operates in the biotechnology industry, focusing on the development of plant-based therapeutics.